Skip to main content
. 2016 Oct 27;7(48):78971–78984. doi: 10.18632/oncotarget.12978

Figure 4. NCoR and TRβ inhibit tumor lymphangiogenesis.

Figure 4

(A) NCoR, TRβ, VEGF-C and VEGF-D mRNA levels in xenografts of MDA and MDA-TRβ cells. Cells were transfected with siControl or siNCoR 72 h before orthotopical inoculation into nude mice and animals were sacrificed 4 weeks later. (B) relative mouse LYVE-1 mRNA levels in the different groups of tumors. (C) representative immunohistochemical staining of LYVE-1 in the tumors, showing the presence of peritumoral lymphatic vessels. Bars: 100 μM.The right panel shows the quantification of the number of lymphatic vessels/microscopic field (means ± S.E) in the tumors. (D) mouse NCoR, VEGF-C and VEGF-D transcripts (means ± S.E) in the xenografts. mRNA levels (means ± S.E) are expressed relative to the values obtained in MDA tumors transfected with siControl. Statistically significant differences between tumors generated from breast cancer cells transfected with siControl and siNCoR, analyzed by ANOVA and Bonferroni post-test, are indicated as * P < 0.05, **P < 0.01 and ***P < 0.001.